Argos Therapeutics
Development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases.
Launch date
Market cap
-
Enterprise valuation
€64—95m (Dealroom.co estimates Nov 2013.)
Durham North Carolina (HQ)
Financials
Estimates*
USD | 2015 | 2016 |
---|---|---|
R&D budget | 62.7m | 38.5m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | N/A | Series B | |
N/A | N/A | Grant | |
N/A | N/A | Grant | |
N/A | N/A | Debt | |
$17.1m | Series C | ||
N/A | $4.9m | Debt | |
N/A | $3.5m | Debt | |
$25.0m | Series D | ||
$42.5m | Series E | ||
$17.5m | Series E | ||
N/A | N/A | IPO | |
$25.0m | Post IPO Debt | ||
N/A | $10.0m | Post IPO Equity | |
$60.0m | Post IPO Equity | ||
N/A | $1.5m | Post IPO Equity | |
Total Funding | €92.8m |
Related Content
Recent News about Argos Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.